Key result
A single 400-mg oral dose of dipyridamole yielded highly variable concentrations, with time to peak ranging from 0.5-2.5 hours and some patients having undetectable levels at injection.
Why the study?
What is the pharmacokinetic disposition of a single 400-mg oral dose of dipyridamole in patients undergoing thallium 201 myocardial imaging?
Observational (n=20)
What is the pharmacokinetic disposition of a single 400-mg oral dose of dipyridamole in patients undergoing thallium 201 myocardial imaging?
A single 400-mg oral dose of dipyridamole for thallium 201 imaging results in highly variable plasma concentrations, potentially limiting its diagnostic reliability in some patients.
Answers are grounded in this paper and cite their sources.
Variable dipyridamole exposure may limit thallium-201 imaging reliability in some patients; leaves open need for optimized protocols or alternatives in prospective studies.
Oral dipyridamole has been used in conjunction with thallium 201 imaging to diagnose coronary artery disease in patients unable to exercise. However, the pharmacokinetic disposition of high-dose dipyridamole, particularly the time to maximum drug concentration, has not been described in patients undergoing oral dipyridamole-thallium 201 scanning. Therefore, we measured serial concentrations in 20 outpatients undergoing thallium 201 testing after a single 400-mg oral dose of dipyridamole. In patients with positive thallium scans (group A), concentrations were slightly higher than in those with negative scans (group B). The variability in concentrations for both groups ranged from 3-118%. The area under the dipyridamole concentration-time curve from 0-4 hours ranged from 2.9-2.3 microgram.hr/ml. The time to peak plasma level for dipyridamole ranged from 0.5-2.5 hours, with two patients having undetectable levels at the time of thallium 201 injection. Dipyridamole concentrations did not correlate with changes in diastolic or systolic blood pressure, or heart rate. Although it is unknown what concentration is required to produce changes in coronary flow velocity, use of oral dipyridamole in this setting resulted in highly variable concentrations. In addition, these data suggest that a small percentage of patients will not have detectable concentrations at the time of the first thallium 201 scan, possibly limiting the usefulness of this agent in conjunction with thallium scintigraphy in some patients.
No takes yet. Share an insight, caveat, or question.
Stringer et al. (1992) conducted an observational in Suspected coronary artery disease (n=20). Oral dipyridamole was evaluated on Pharmacokinetic disposition (time to maximum drug concentration). A single 400-mg oral dose of dipyridamole yielded highly variable concentrations, with time to peak ranging from 0.5-2.5 hours and some patients having undetectable levels at injection.
Synapse has enriched 10 related papers. Consider them for comparative context: